Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report

Published:2012-10-05 Issue:1 Volume:5 Page:
ISSN:1756-0500
Container-title:BMC Research Notes
language:en
Short-container-title:BMC Res Notes

Author:

Colomba Claudia,Rubino Raffaella,Siracusa Lucia,Lalicata Francesco,Trizzino Marcello,Titone Lucina,Tolomeo Manlio

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1756-0500-5-552.pdf

Reference8 articles.

1. Baxter EJ, Scott LM, Campbell PJ: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005, 365 (9464): 1054-1061.

2. Kralovics R, Passamonti F, Buser AS: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352 (17): 1779-1790. 10.1056/NEJMoa051113.

3. Tefferi A: Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2011, 86 (12): 1017-1026. 10.1002/ajh.22210.

4. Deisseroth AB, Kaminskas E, Grillo J, Chen W, Saber H, Lu H, Rothmann MD, Brar SS, Wang J, Garnett C, Bullock J, Burke L, Rahman A, Sridhara R, Farrell A: US Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with intermediate and high Risk Myelofibrosis. Clin Cancer Res. 2012, 15 (12): 3212-3217.

5. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012, 366 (9): 787-798. 10.1056/NEJMoa1110556.

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Miliary TB and COVID-19 Coinfection in a Patient With a History of Post-polycythemia Vera Myelofibrosis Treated With Ruxolitinib: A Case Report;Cureus;2024-07-03

2. Ruxolitinib associated psoas muscle tuberculosis abscess in a primary myelofibrosis woman: A case report and literature review;Medicine;2024-04-05

3. Advances in Janus-Associated Kinase Inhibitor-Based Therapies for Philadelphia Chromosome–Negative Myeloproliferative Neoplasms;Advances in Oncology;2022-05

4. A case of disseminated BCG infection in a daughter of Italian immigrants in Switzerland;The Journal of Infection in Developing Countries;2022-02-28

5. Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review;Internal Medicine;2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3